Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 58

Results For "Pharmaceuticals"

1620 News Found

Glenmark Pharma launches Empagliflozin and its fixed-drug combinations in India
News | March 13, 2025

Glenmark Pharma launches Empagliflozin and its fixed-drug combinations in India

Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M


Emcure partners with Vidya Balan for Arth supplements,
News | March 11, 2025

Emcure partners with Vidya Balan for Arth supplements,

Vidya will spark conversations around less discussed and important aspects of health, including intimate care and sleep issues


Glenmark Nutrition Awards 2025 celebrates innovation and impact in fight against malnutrition
News | March 10, 2025

Glenmark Nutrition Awards 2025 celebrates innovation and impact in fight against malnutrition

403 entries from 22 states covering 168 districts highlight groundbreaking initiatives vital to improving national nutrition metrics.


Amaran Biotech signs MOU with Nippon Fine Chemical to expand CDMO business
News | March 08, 2025

Amaran Biotech signs MOU with Nippon Fine Chemical to expand CDMO business

Amaran Biotech boasts Taiwan’s first fully automated robotic aseptic filling line, offering high-quality and low-waste filling solutions for high-value pharmaceuticals


Lupin Launches Rivaroxaban Tablets USP, 2.5mg in US
Drug Approval | March 07, 2025

Lupin Launches Rivaroxaban Tablets USP, 2.5mg in US

Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals


PMBJP has led to a total savings of Rs. 30,000 crore for citizens: Health Minister Nadda
Policy | March 03, 2025

PMBJP has led to a total savings of Rs. 30,000 crore for citizens: Health Minister Nadda

In financial year 2024-25, PMBJP has made sales of Rs. 1,760 crore (at MRP) till Feb 2025


Briefs: Emcure and Relonchem
Drug Approval | February 27, 2025

Briefs: Emcure and Relonchem

USFDA inspection at Emcure Pharmaceuticals API facility


Teva and Sanofi present new outcome from Phase 2b study of duvakitug
News | February 25, 2025

Teva and Sanofi present new outcome from Phase 2b study of duvakitug

Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025


Sandeep Rao appointed MD and CEO of Solar Active Pharma Sciences
People | February 23, 2025

Sandeep Rao appointed MD and CEO of Solar Active Pharma Sciences

Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025